arrow
S

Sarwish Rafiq

Emory University
H指数:19
被引数:4,405

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Modulating the VIP-VIPR pathway reprograms CAR T cells for superior antitumor efficacy in preclinical cancer models

通过调节VIP-VIPR通路重编程CAR T细胞,在预临床癌症模型中实现更优的抗肿瘤效果

2026-07-220
PRE
Combination radiation and αPD-L1 enhance tumor control by stimulating CD8+PD-1+TCF-1+T cells in the tumor-draining lymph node

联合放疗和αPD-L1通过刺激肿瘤引流淋巴结中的CD8+PD-1+TCF-1+T细胞来增强肿瘤控制。

2025-04-140
OA
Engineering Improved Car T Cell Products with A Multi-Cytokine Particle Platform for Hematologic and Solid Tumors

用多细胞因子颗粒平台改造改良的Car T细胞产品,用于血液和实体瘤

2024-02-141
PRE
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity

反式疫苗酸重新编程CD8 T细胞和抗肿瘤免疫

Nature
IF48.5
2023-11-220
OAAI
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Car-t细胞靶向递送PD-1-blocking scFv增强体内抗肿瘤功效

2018-10-01655
OAAI
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies
MABS
IF7.3
2014-10-278
OAAI
Ocaratuzumab, an Fc- engineered antibody demonstrates enhanced antibody- dependent cell- mediated cytotoxicity in chronic lymphocytic leukemia

Fc工程抗体Ocaratuzumab在慢性淋巴细胞白血病中显示出增强的抗体依赖性细胞介导的细胞毒性

MABS
IF7.3
2014-03-0439
OAAI